三生国健：辉瑞10月30日在ClinicalTrials.gov网站上登记了PD-1/VEGF双抗PF-08634404（SSGJ-707）的两项全球III期临床试验

Core Viewpoint - Sanofi has granted Pfizer exclusive rights for the development, production, and commercialization of the dual-targeting antibody product SSGJ-707, which targets both PD-1 and VEGF, under a licensing agreement that will take effect on July 24, 2025 [1] Group 1: Licensing Agreement Details - The licensing agreement involves a product known as project 707, which is a dual-specific antibody targeting PD-1 and VEGF [1] - All payments made by Pfizer to the licensors will be distributed between the company and Shenyang Sanofi [1] - The agreement includes milestone payments that are contingent upon meeting specific conditions, leading to uncertainty regarding final payments [1] Group 2: Clinical Trials - On October 30, 2025, Pfizer registered two global Phase III clinical trials for the PD-1/VEGF dual antibody PF-08634404 (SSGJ-707) on ClinicalTrials.gov [1]